is predicted to increase the exposure to paclitaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Clopidogrel is predicted to increase the concentration of

paclitaxel.rAnecdotal

▶ Cobicistat is predicted to increase the exposure to cabazitaxel.

Avoid.rStudy

▶ Cobicistat is predicted to moderately increase the exposure to

docetaxel. Avoid or adjust dose.rStudy

▶ Cobicistat

r

is predicted to increase the exposure to paclitaxel.

Theoretical

▶ Crizotinib

o

is predicted to increase the exposure to cabazitaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Efavirenz is predicted to decrease the exposure to cabazitaxel.

Avoid.rStudy

▶ Eliglustat is predicted to increase the exposure to paclitaxel.

Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

docetaxel.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to taxanes

(cabazitaxel, paclitaxel). Avoid.rStudy

▶ Fibrates (gemfibrozil) are predicted to increase the

concentration of paclitaxel.rAnecdotal

▶ HIV-protease inhibitors are predicted to increase the exposure

to cabazitaxel. Avoid.rStudy

▶ HIV-protease inhibitors are predicted to moderately increase

the exposure to docetaxel. Avoid or adjust dose.rStudy

▶ HIV-protease inhibitors are predicted to increase the exposure

to paclitaxel.rTheoretical

▶ Idelalisib is predicted to increase the exposure to cabazitaxel.

Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to moderately increase the exposure to

docetaxel. Avoid or adjust dose.rStudy → Also see TABLE 15

p. 1378

▶ Idelalisib

r

is predicted to increase the exposure to paclitaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Imatinib

o

is predicted to increase the exposure to cabazitaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Lapatinib

Study

slightly increases the exposure to paclitaxel.r

▶ Leflunomide is predicted to increase the concentration of

paclitaxel.rAnecdotal → Also see TABLE 15 p. 1378

▶ Live vaccines are predicted to increase the risk of generalised

infection (possibly life-threatening) when given with taxanes

(docetaxel, paclitaxel). Public Health England advises avoid

(refer to Green Book).rTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to cabazitaxel. Avoid.rStudy

▶ Macrolides (clarithromycin) are predicted to moderately

increase the exposure to

r

docetaxel. Avoid or adjust dose.

Study

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to paclitaxel.rTheoretical

▶ Macrolides (erythromycin) are predicted to increase the

exposure to cabazitaxel.oTheoretical

▶ Mirabegron is predicted to increase the exposure to paclitaxel.

nTheoretical

▶ Mitotane

r

is predicted to decrease the exposure to docetaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Mitotane is predicted to decrease the exposure to taxanes

(cabazitaxel, paclitaxel). Avoid.rStudy → Also see TABLE 15

p. 1378

▶ Netupitant

o

is predicted to increase the exposure to cabazitaxel.

Theoretical

▶ Netupitant

o

slightly increases the exposure to docetaxel.

Study

▶ Netupitant

o

is predicted to increase the exposure to paclitaxel.

Study

▶ Nevirapine is predicted to decrease the exposure to

cabazitaxel. Avoid.rStudy

▶ Nilotinib

o

is predicted to increase the exposure to cabazitaxel.

Theoretical → Also see TABLE 15 p. 1378

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to paclitaxel.oStudy

▶ Pibrentasvir (with glecaprevir) is predicted to increase the

exposure to paclitaxel.oStudy

▶ Pitolisant is predicted to decrease the exposure to docetaxel.

Avoid.rTheoretical

▶ Pitolisant is predicted to decrease the exposure to paclitaxel.

nTheoretical

▶ Rifampicin

r

is predicted to decrease the exposure to docetaxel.

Theoretical

▶ Rifampicin is predicted to decrease the exposure to taxanes

(cabazitaxel, paclitaxel). Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

cabazitaxel. Avoid.rStudy

▶ Teriflunomide is predicted to increase the concentration of

paclitaxel.rAnecdotal

▶ Velpatasvir

r

is predicted to increase the exposure to paclitaxel.

Theoretical

Tazarotene → see retinoids

Tedizolid

▶ Tedizolid is predicted to increase the exposure to imatinib.

Avoid.oTheoretical

▶ Tedizolid is predicted to increase the exposure to lapatinib.

Avoid.oTheoretical

▶ Tedizolid is predicted to increase the exposure to

methotrexate. Avoid.oTheoretical

▶ Tedizolid is predicted to increase the exposure to statins

(atorvastatin, fluvastatin, rosuvastatin). Avoid.oStudy

▶ Tedizolid is predicted to increase the exposure to sulfasalazine.

Avoid.oStudy

▶ Tedizolid is predicted to increase the exposure to topotecan.

Avoid.oStudy

Tegafur

▶ Tegafur potentially increases the concentration of

antiepileptics (fosphenytoin, phenytoin). Monitor concentration

and adjust dose.rAnecdotal

▶ Tegafur

o

increases the anticoagulant effect of coumarins.

Theoretical

▶ Folates are predicted to increase the risk of toxicity when

given with tegafur.rTheoretical

▶ H2 receptor antagonists (cimetidine) are predicted to increase

the risk of toxicity when given with tegafur.rTheoretical

▶ Live vaccines are predicted to increase the risk of generalised

infection (possibly life-threatening) when given with tegafur.

Public Health England advises avoid (refer to Green Book).

rTheoretical

1540 Taxanes —Tegafur BNF 78

Interactions | Appendix 1

A1

▶ Methotrexate is predicted to increase the risk of toxicity when

given with tegafur.rTheoretical

Teicoplanin

GENERAL INFORMATION If other nephrotoxic or neurotoxic

drugs are given, monitor renal and auditory function on

prolonged administration.

Telavancin → see TABLE 2 p. 1375 (nephrotoxicity), TABLE 19 p. 1379

(ototoxicity), TABLE 9 p. 1377 (QT-interval prolongation)

Telbivudine

▶ Interferons (interferon alfa) are predicted to increase the risk of

peripheral neuropathy when given with

r

telbivudine. Avoid.

Theoretical

▶ Interferons (peginterferon alfa) increase the risk of peripheral

neuropathy when given with telbivudine. Avoid.rStudy

Telmisartan → see angiotensin-II receptor antagonists

Telotristat ethyl

▶ Telotristat ethyl is predicted to decrease the exposure to

doravirine

Theoretical

. Avoid or adjust doravirine dose, p. 644.r

▶ Telotristat ethyl

o

decreases the exposure to midazolam.

Study

▶ Octreotide (short-acting) decreases the exposure to telotristat

ethyl. Telotristat ethyl should be taken at least 30 minutes

before octreotide.oStudy

Temazepam → see TABLE 11 p. 1377 (CNS depressant effects)

Temocillin → see penicillins

Temozolomide → see alkylating agents

Temsirolimus → see TABLE 15 p. 1378 (myelosuppression)

▶ Antiarrhythmics (dronedarone) are predicted to increase the

concentration of temsirolimus.oTheoretical

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the

concentration of temsirolimus. Avoid.rStudy

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the concentration of

o

temsirolimus.

Theoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the concentration of temsirolimus.

Avoid.rTheoretical

▶ Apalutamide is predicted to decrease the exposure to

temsirolimus. Avoid or monitor.oStudy

▶ Aprepitant is predicted to increase the concentration of

temsirolimus.oTheoretical

▶ Bosentan is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the concentration of

Theoretical

temsirolimus.o ▶ Cobicistat is predicted to increase the concentration of

temsirolimus. Avoid.rTheoretical

▶ Crizotinib is predicted to increase the concentration of

temsirolimus.oTheoretical → Also see TABLE 15 p. 1378

▶ Efavirenz is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

temsirolimus. Avoid.rStudy

▶ Grapefruit juice is predicted to increase the concentration of

temsirolimus. Use with caution or avoid.oTheoretical

▶ HIV-protease inhibitors are predicted to increase the

concentration of temsirolimus. Avoid.rTheoretical

▶ Idelalisib is predicted to increase the concentration of

temsirolimus. Avoid.rTheoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the concentration of

temsirolimus.oTheoretical → Also see TABLE 15 p. 1378

▶ Live vaccines are predicted to increase the risk of generalised

infection (possibly life-threatening) when given with

temsirolimus. Public Health England advises avoid (refer to

Green Book).rTheoretical

▶ Lumacaftor is predicted to decrease the exposure to

temsirolimus. Avoid.rTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the

concentration of temsirolimus. Avoid.rTheoretical

▶ Macrolides (erythromycin) are predicted to increase the

concentration of temsirolimus.oTheoretical

▶ Mitotane is predicted to decrease the concentration of

temsirolimus. Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Netupitant is predicted to increase the concentration of

temsirolimus.oTheoretical

▶ Nevirapine is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ Nilotinib is predicted to increase the concentration of

temsirolimus.oTheoretical → Also see TABLE 15 p. 1378

▶ Pitolisant is predicted to decrease the exposure to

temsirolimus. Avoid.rTheoretical

▶ Rifampicin is predicted to decrease the concentration of

temsirolimus. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

Tenecteplase → see TABLE 3 p. 1375 (anticoagulant effects)

Tenofovir alafenamide

▶ Antiepileptics (carbamazepine, fosphenytoin, oxcarbazepine,

phenobarbital, phenytoin, primidone) are predicted to decrease

the exposure to

Theoretical

tenofovir alafenamide. Avoid.o ▶ Ciclosporin is predicted to increase the exposure to tenofovir

alafenamide.oTheoretical

▶ Eltrombopag is predicted to increase the exposure to tenofovir

alafenamide.oTheoretical

▶ HIV-protease inhibitors (atazanavir, darunavir, lopinavir) increase

the exposure to

o

tenofovir alafenamide. Avoid or adjust dose.

Study

▶ HIV-protease inhibitors (tipranavir) are predicted to decrease the

exposure to tenofovir alafenamide. Avoid.oTheoretical

▶ Leflunomide is predicted to increase the exposure to tenofovir

alafenamide.oTheoretical

▶ Rifabutin is predicted to decrease the exposure to tenofovir

alafenamide. Avoid.oTheoretical

▶ Rifampicin is predicted to decrease the exposure to tenofovir

alafenamide. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tenofovir alafenamide. Avoid.oTheoretical

▶ Teriflunomide is predicted to increase the exposure to

tenofovir alafenamide.oTheoretical

Tenofovir disoproxil → see TABLE 2 p. 1375 (nephrotoxicity)

▶ Ciclosporin is predicted to increase the exposure to tenofovir

disoproxil.oTheoretical → Also see TABLE 2 p. 1375

▶ Tenofovir disoproxil increases the risk of toxicity when given

with didanosine. Avoid.rStudy

▶ Eltrombopag is predicted to increase the exposure to tenofovir

disoproxil.oTheoretical

▶ HIV-protease inhibitors (atazanavir, darunavir, lopinavir) are

predicted to increase the risk of renal impairment when given

with tenofovir disoproxil.rAnecdotal

▶ Ledipasvir (with sofosbuvir) slightly increases the exposure to

tenofovir disoproxil.oStudy

▶ Leflunomide is predicted to increase the exposure to tenofovir

disoproxil.oTheoretical

▶ Teriflunomide is predicted to increase the exposure to

tenofovir disoproxil.oTheoretical

▶ Velpatasvir is predicted to increase the exposure to tenofovir

disoproxil.rStudy

▶ Voxilaprevir (with sofosbuvir and velpatasvir) potentially

increases the concentration of

Study

tenofovir disoproxil.r

Tenoxicam → see NSAIDs

Terazosin → see alpha blockers

Terbinafine

ROUTE-SPECIFIC INFORMATION Since systemic absorption can

follow topical application, the possibility of interactions

should be borne in mind.

▶ Terbinafine is predicted to increase the exposure to

anticholinesterases, centrally acting (galantamine). Monitor and

adjust dose.oStudy

▶ Terbinafine is predicted to moderately increase the exposure

to aripiprazole. Adjust aripiprazole dose, p. 395.oStudy

▶ Terbinafine is predicted to markedly increase the exposure to

atomoxetine. Adjust dose.rStudy

▶ Terbinafine is predicted to increase the exposure to beta

blockers, selective (metoprolol, nebivolol).oStudy

BNF 78 Tegafur —Terbinafine 1541

Interactions | Appendix 1

A1

Terbinafine (continued)

▶ Terbinafine is predicted to slightly increase the exposure to

darifenacin.nStudy

▶ Terbinafine is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Terbinafine

o

is predicted to increase the exposure to mexiletine.

Study

▶ Terbinafine is predicted to decrease the efficacy of opioids

(codeine).oTheoretical

▶ Terbinafine is predicted to decrease the efficacy of opioids

(tramadol).rStudy

▶ Terbinafine is predicted to moderately increase the exposure

to pitolisant. Use with caution and adjust dose.oStudy

▶ Rifampicin

o

decreases the exposure to terbinafine. Adjust dose.

Study

▶ Terbinafine is predicted to increase the exposure to

risperidone. Adjust dose.oStudy

▶ Terbinafine is predicted to increase the exposure to SSRIs

(citalopram, dapoxetine, escitalopram, fluvoxamine, sertraline)

o .

Theoretical

▶ Terbinafine is predicted to increase the exposure to SSRIs

(fluoxetine). Adjust dose.oTheoretical

▶ Terbinafine moderately increases the exposure to SSRIs

(paroxetine).oStudy

▶ Terbinafine is predicted to decrease the efficacy of tamoxifen.

Avoid.rStudy

▶ Terbinafine is predicted to increase the exposure to tricyclic

antidepressants

Study

. Monitor for toxicity and adjust dose.r

▶ Terbinafine is predicted to increase the exposure to

vortioxetine. Monitor and adjust dose.oStudy

Terbutaline → see beta2 agonists

Teriflunomide

▶ Teriflunomide

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more